A085660 Stock Overview
A bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Chabiotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩16,800.00 |
| 52 Week High | ₩21,000.00 |
| 52 Week Low | ₩13,510.00 |
| Beta | 0.19 |
| 11 Month Change | -0.89% |
| 3 Month Change | 5.46% |
| 1 Year Change | 2.94% |
| 33 Year Change | -14.72% |
| 5 Year Change | 7.01% |
| Change since IPO | 125.10% |
Recent News & Updates
Recent updates
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business
Aug 07
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?
Mar 01If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%
Jan 25The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About
Dec 21Shareholder Returns
| A085660 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | -1.5% | -6.6% | -1.2% |
| 1Y | 2.9% | 1.8% | 4.8% |
Return vs Industry: A085660 underperformed the KR Healthcare industry which returned 19.7% over the past year.
Return vs Market: A085660 underperformed the KR Market which returned 7.2% over the past year.
Price Volatility
| A085660 volatility | |
|---|---|
| A085660 Average Weekly Movement | 6.4% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.3% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A085660 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A085660's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 271 | Hoon Oh Sang | www.chabio.com |
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.
Chabiotech Co.,Ltd. Fundamentals Summary
| A085660 fundamental statistics | |
|---|---|
| Market cap | ₩946.08b |
| Earnings (TTM) | -₩22.48b |
| Revenue (TTM) | ₩974.80b |
1.0x
P/S Ratio-42.1x
P/E RatioIs A085660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A085660 income statement (TTM) | |
|---|---|
| Revenue | ₩974.80b |
| Cost of Revenue | ₩722.13b |
| Gross Profit | ₩252.67b |
| Other Expenses | ₩275.15b |
| Earnings | -₩22.48b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -399.21 |
| Gross Margin | 25.92% |
| Net Profit Margin | -2.31% |
| Debt/Equity Ratio | 63.2% |
How did A085660 perform over the long term?
See historical performance and comparison